Relypsa to Present at Wedbush PacGrow Lifesciences 2014 Conference

By GlobeNewswire,  August 07, 2014, 04:00:00 PM EDT


REDWOOD CITY, Calif., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that John Orwin, Chief Executive Officer, will present a corporate overview at the Wedbush PacGrow Lifesciences Conference on August 13, 2014 at 9:10 a.m. ET.

To access the live webcasts and subsequent archived recordings of these presentations, please visit Relypsa's website at www.relypsa.com.

About Relypsa, Inc.

Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The company's two-part pivotal Phase 3 trial of its lead product candidate, patiromer, for the treatment of hyperkalemia, a life-threatening condition defined as abnormally elevated levels of potassium in the blood, has been completed and the primary and secondary endpoints were met. Relypsa has global royalty-free commercialization rights to patiromer, which has intellectual property protection in the U.S. until at least 2030. More information is available at www.relypsa.com.

CONTACT: Sylvia Wheeler
         V.P. Investor Relations and Corporate Affairs
         650-421-9504
         IR@relypsa.com

Source: Relypsa, Inc.

This article appears in: News Headlines

Referenced Stocks: RLYP


Latest News Video





Most Active by Volume

Company Last Sale Change Net / %
F $ 13.78 0.62 ▼ 4.31%
PBR $ 12.93 0.82 ▲ 6.77%
MSFT $ 46.13 1.11 ▲ 2.47%
AAPL $ 105.22 0.39 ▲ 0.37%
PBR/A $ 13.46 1.10 ▲ 8.90%
QQQ $ 98.62 0.80 ▲ 0.82%
BAC $ 16.72 0.12 ▲ 0.72%
VALE $ 11.16 0.33 ▲ 3.05%

As of 10/24/2014, 04:15 PM